Rhythmic activity from transverse brainstem slice of neonatal rat is modulated by nitric oxide.
We investigated the role of nitric oxide (NO) in the modulation of respiratory-like activity recorded from hypoglossal rootlets in brainstem slices of neonatal rats (P0-P8). Sodium nitroprusside (SNP), S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) and diethylamine-NO (DEA-NO), three NO-donors, reversibly increased hypoglossal burst amplitude with inconsistent effects on burst frequency. Similar effects were also obtained with the endogenous substrate of nitric oxide synthase (NOS), L-arginine, whereas the inactive enantiomer D-arginine had no effect. The NO-trap agent methylene blue significantly depressed both the amplitude and frequency of hypoglossal activity while hemoglobin depressed only the amplitude. Furthermore, the addition of NO-trap agents significantly attenuated the excitatory response to SNP. Inhibiting NOS with either N(omega)-Nitro-L-Arginine (L-NNA) or 7-Nitroindazole (7-NI), decreased the amplitude of hypoglossal activity with no effects on frequency. Histochemical analysis of NADPH-diaphorase activity, a marker for NOS, was performed on slices not treated pharmacologically and in brainstem sections of newborn rats, perfused in situ. Comparison between in vitro and in vivo conditions indicated that NOS activity was maintained in slice preparations. Neurons in the ambiguus and hypoglossal nuclei (dorsal division) exhibited a granular staining, suggesting the presence of NADPHd-positive terminals. Neurons with cytoplasmic staining were identified in regions connected to the hypoglossal nucleus (nucleus tractus solitarius, paramedian and gigantocellular reticular nuclei). These neurons might be involved in nitrergic control of hypoglossal activity. Both pharmacological and histochemical data suggest that endogenous NO may reinforce the output activity of the medullary respiratory network.
Pierrefiche
O
O
ETP-APC, EA2088 - Laboratoire de Neurophysiologie, UFR de Médecine, 3 rue des Louvels, 80036, Amiens, France. op-lnc@u-picardie.fr
Maniak
F
F
Larnicol
N
N
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D000831:Animals, Newborn; D001933:Brain Stem / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006651:Histocytochemistry; D006834:Hydrazines / Q000494:pharmacology; D066298:In Vitro Techniques; D009249:NADP / Q000378:metabolism; D009569:Nitric Oxide / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D019335:Nitroarginine / Q000494:pharmacology; D009589:Nitrogen Oxides; D009599:Nitroprusside / Q000494:pharmacology; D010396:Penicillamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats
D004791:Enzyme Inhibitors; D006834:Hydrazines; D020030:Nitric Oxide Donors; D009589:Nitrogen Oxides; C110881:S-nitro-N-acetylpenicillamine; D009599:Nitroprusside; D019335:Nitroarginine; D009569:Nitric Oxide; D009249:NADP; C084012:1,1-diethyl-2-hydroxy-2-nitrosohydrazine; D019001:Nitric Oxide Synthase; D010396:Penicillamine